Trials Sponsors Conditions Drugs Pricing

Conditions

Coronary Disease Percutaneous Transluminal Coronary Angioplasty

Keywords

DAPTBVSBioresorbable Vascular ScaffoldDual Antiplatelet Therapy

Outcome Measures

Primary Outcomes (1)

composite event of death, myocardial infarction, or stroke
1 year

Secondary Outcomes (7)

Death
5 years
Myocardial Infarction
5 years
Stroke
5 years
Target Vessel Revascularization
5 years
Target Lesion Revascularization
5 years
+2 more secondary outcomes

Study Arms (2)

DAPT

EXPERIMENTAL

Dual antiplatelet therapy : aspirin and clopidogrel

Drug: aspirin and clopidogrel

Clopidogrel only

ACTIVE COMPARATOR

Clopidogrel monotherapy

Drug: Clopidogrel only

Interventions

aspirin and clopidogrelDrug

at the discretion of investigator

DAPT

Clopidogrel onlyDrug

at the discretion of investigator

Clopidogrel only

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Grouped treatment entry
aspirin and clopidogrel
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record

Eligibility Criteria

Age19 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Men or women at least 19 years of age
Patients undergoing dual- or triple-antiplatelet therapy at least 12-14 months after PCI with BVS

Sponsors & Collaborators

Seung-Jung Park
Otherlead
CardioVascular Research Foundation, Korea
Othercollaborator

Study Sites (2)

Asan Medical Center

Seoul, Songpa-gu, 138-736, South Korea

Chonnam National University Hospital

Gwangju, South Korea

MeSH Terms

Conditions

Coronary Disease

Interventions

AspirinClopidogrel

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular Diseases

Intervention Hierarchy (Ancestors)

SalicylatesHydroxybenzoatesPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, Cyclic

Enrollment

238 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 4
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR INVESTIGATOR
PI Title: professor, Division of Cardiology, Department of Internal Medicine

Study Record Dates

First Submitted

October 18, 2016

First Posted

October 20, 2016

Study Start

March 9, 2017

Actual (reported)

Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (7)

Study Arms (2)

DAPT

Clopidogrel only

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (7)

Study Arms (2)

DAPT

Clopidogrel only

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations